tiprankstipranks
Advertisement
Advertisement

AMLX Stock Latest News

Amylyx price target raised to $24 from $21 at Mizuho
The FlyAmylyx price target raised to $24 from $21 at Mizuho
20h ago
AMLX
Amylyx price target raised to $40, named a Best Idea at Guggenheim
PremiumThe Fly
Amylyx price target raised to $40, named a Best Idea at Guggenheim
26d ago
AMLX
Amylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial
PremiumThe Fly
Amylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial
28d ago
AMLX
Amylyx Shareholders Approve Directors, Auditor and Executive Pay
PremiumCompany Announcements
Amylyx Shareholders Approve Directors, Auditor and Executive Pay
2M ago
8K
AMLX
Amylyx announces publication of Phase 2 open-label HELIOS trial data
PremiumThe Fly
Amylyx announces publication of Phase 2 open-label HELIOS trial data
2M ago
AMLX
Amylyx Pharmaceuticals Charts Path to 2026 Trial Data
PremiumCompany AnnouncementsAmylyx Pharmaceuticals Charts Path to 2026 Trial Data
2M ago
AMLX
Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target
Premium
Ratings
Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target
2M ago
AMLX
Amylyx reports Q1 EPS (37c), consensus (34c)
Premium
The Fly
Amylyx reports Q1 EPS (37c), consensus (34c)
2M ago
AMLX
Amylyx sees cash runway into 2028
PremiumThe Fly
Amylyx sees cash runway into 2028
2M ago
AMLX
Amylyx announces launch of U.S. EAP for adults with PBH
PremiumThe Fly
Amylyx announces launch of U.S. EAP for adults with PBH
3M ago
AMLX
Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch
PremiumCompany Announcements
Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch
3M ago
AMLX
Amylyx price target raised to $21 from $19 at Mizuho
PremiumThe Fly
Amylyx price target raised to $21 from $19 at Mizuho
3M ago
AMLX
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential
PremiumRatingsBuy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential
3M ago
AMLX
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
Premium
Company Announcements
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
4M ago
8K
AMLX
Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
Premium
The Fly
Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
4M ago
AMLX
Amylyx price target raised to $30 from $25 at Guggenheim
PremiumThe Fly
Amylyx price target raised to $30 from $25 at Guggenheim
4M ago
AMLX
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program
PremiumRatings
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program
4M ago
AMLX
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027
PremiumCompany Announcements
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027
4M ago
AMLX
Amylyx price target raised to $34 from $28 at H.C. Wainwright
PremiumThe Fly
Amylyx price target raised to $34 from $28 at H.C. Wainwright
5M ago
AMLX
Amylyx Pharmaceuticals: Solid Balance Sheet, Advancing Pipeline, and Attractive Risk‑Reward Support Buy Rating
PremiumRatingsAmylyx Pharmaceuticals: Solid Balance Sheet, Advancing Pipeline, and Attractive Risk‑Reward Support Buy Rating
5M ago
AMLX
Amylyx files automatic mixed securities shelf
Premium
The Fly
Amylyx files automatic mixed securities shelf
5M ago
AMLX
Amylyx reports Q4 EPS (30c), consensus (34c)
Premium
The Fly
Amylyx reports Q4 EPS (30c), consensus (34c)
5M ago
AMLX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >